Cargando…
An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571951/ https://www.ncbi.nlm.nih.gov/pubmed/34841699 http://dx.doi.org/10.1002/ctm2.572 |
| _version_ | 1784595127593861120 |
|---|---|
| author | Findlay, Alison Turner, Craig Schilter, Heidi Deodhar, Mandar Zhou, Wenbin Perryman, Lara Foot, Jonathan Zahoor, Amna Yao, Yimin Hamilton, Ross Brock, Mary Raso, Christina Stolp, Jessica Galati, Marie Hamprecht, Dieter Charlton, Brett Jarolimek, Wolfgang |
| author_facet | Findlay, Alison Turner, Craig Schilter, Heidi Deodhar, Mandar Zhou, Wenbin Perryman, Lara Foot, Jonathan Zahoor, Amna Yao, Yimin Hamilton, Ross Brock, Mary Raso, Christina Stolp, Jessica Galati, Marie Hamprecht, Dieter Charlton, Brett Jarolimek, Wolfgang |
| author_sort | Findlay, Alison |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8571951 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85719512021-11-10 An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies Findlay, Alison Turner, Craig Schilter, Heidi Deodhar, Mandar Zhou, Wenbin Perryman, Lara Foot, Jonathan Zahoor, Amna Yao, Yimin Hamilton, Ross Brock, Mary Raso, Christina Stolp, Jessica Galati, Marie Hamprecht, Dieter Charlton, Brett Jarolimek, Wolfgang Clin Transl Med Letter to Editor John Wiley and Sons Inc. 2021-11-06 /pmc/articles/PMC8571951/ /pubmed/34841699 http://dx.doi.org/10.1002/ctm2.572 Text en © 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to Editor Findlay, Alison Turner, Craig Schilter, Heidi Deodhar, Mandar Zhou, Wenbin Perryman, Lara Foot, Jonathan Zahoor, Amna Yao, Yimin Hamilton, Ross Brock, Mary Raso, Christina Stolp, Jessica Galati, Marie Hamprecht, Dieter Charlton, Brett Jarolimek, Wolfgang An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies |
| title | An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies |
| title_full | An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies |
| title_fullStr | An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies |
| title_full_unstemmed | An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies |
| title_short | An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies |
| title_sort | activity‐based bioprobe differentiates a novel small molecule inhibitor from a loxl2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies |
| topic | Letter to Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571951/ https://www.ncbi.nlm.nih.gov/pubmed/34841699 http://dx.doi.org/10.1002/ctm2.572 |
| work_keys_str_mv | AT findlayalison anactivitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT turnercraig anactivitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT schilterheidi anactivitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT deodharmandar anactivitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT zhouwenbin anactivitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT perrymanlara anactivitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT footjonathan anactivitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT zahooramna anactivitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT yaoyimin anactivitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT hamiltonross anactivitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT brockmary anactivitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT rasochristina anactivitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT stolpjessica anactivitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT galatimarie anactivitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT hamprechtdieter anactivitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT charltonbrett anactivitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT jarolimekwolfgang anactivitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT findlayalison activitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT turnercraig activitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT schilterheidi activitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT deodharmandar activitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT zhouwenbin activitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT perrymanlara activitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT footjonathan activitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT zahooramna activitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT yaoyimin activitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT hamiltonross activitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT brockmary activitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT rasochristina activitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT stolpjessica activitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT galatimarie activitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT hamprechtdieter activitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT charltonbrett activitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies AT jarolimekwolfgang activitybasedbioprobedifferentiatesanovelsmallmoleculeinhibitorfromaloxl2antibodyandprovidesrenewedpromiseforantifibrotictherapeuticstrategies |